The global organ transplant immunosuppressant drugs market is exhibiting a CAGR of -5.0% within a forecast period from 2015 to 2023. The market was registered at US$5.1 bn in 2014. It is expected to shrink to US$3.2 bn by the end of 2023, according to a research report released by Transparency Market Research. The report is titled “Organ Transplant Immunosuppressant Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”
Browse the full Organ Transplant Immunosuppressant Drugs Market: (By Drug Class: Calcineurin Inhibitors, Anti-proliferative Agents, mTOR Inhibitors, Antibodies, and Steroids; By Transplant: Kidney, Bone Marrow, Liver, Heart, Lung, and Others): Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 report at https://www.transparencymarketresearch.com/organ-transplant-immunosuppressant-drugs.html
According to the report, there are multiple factors restraining the global organ transplant immunosuppressant drugs market. The greatest restraint on this market is the imbalance in the supply and demand chain. Other factors hampering the global organ transplant immunosuppressant drugs market include the high cost of availing the procedure, coupled with unfavorable reimbursement policies, along with the advent of new and more favorable technologies.
Modern medicine has created alternatives to organ transplant immunosuppressant drugs, such as the growing use of stem cells. The market is further restricted by a severe lack of healthy donor organs.
The global organ transplant immunosuppressant drugs market is currently being boosted by the growing incidence of chronic diseases. However, the ratio of healthy donor organs to patients in need is askew, creating large-scale shortages of available organs.
The report provides a segmented analysis of the global organ transplant immunosuppressant drugs market in terms of drug class, transplant, and geography.
In terms of drug classes, the global organ transplant immunosuppressant drugs market was led by the segment of calcineurin inhibitors in 2014. In that year, the segment was calculated at US$2.3 bn. At the same time, a major number of patients are usually prescribed tacrolimus in order to maintain the schedule of the immunosuppression. This procedure shows higher potency as well as a lower rejection rate as opposed to cyclosporine.
Oral prednisone, prednisolone, and methyl prednisolone are the three most common types of corticosteroids utilized during organ transplant. Corticosteroids are usually administered to patients in the initial stages of organ transplantation.
The report’s segmentation based on organ transplant shows that the global organ transplant immunosuppressant drugs market was dominated by the segment of kidney transplants in 2014, when it held over half the market. It is expected that the kidney transplant segment will dominate the market in the given forecast period.
From a geographical perspective, the report reveals North America to have led the global organ transplant immunosuppressant drugs market in 2013. This region has benefitted largely from the high rate of organ transplants in the United States. The U.S. consists of a large number of advanced medical facilities that offer organ transplant procedures. The nation’s healthcare industry also offers advanced surgical procedures and modern and enhanced immunosuppressive drugs. This has led to a high success rate of organ transfer procedures.
The key players in the global organ transplant immunosuppressant drugs market are Pfizer, Bristol-Myers Squibb Company, Sanofi, Novartis, AbbVie, Allergan, and Astellas Pharma.
Key segments of the Global Organ Transplant Immunosuppressant Market
Global Organ Transplant Immunosuppressant Drugs, by Drug Class
- Calcineurin Inhibitors
- Antiproliferative Agents
- Mycophenolate Mofetil
- Mycophenolate Sodium
- mTOR Inhibitors
- Antithymocyte Globulin
Global Organ Transplant Immunosuppressant Drugs, by Transplant
- Bone Marrow
- Others (Intestinal and Multi-visceral Organs)
Global Organ Transplant Immunosuppressant Drugs, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Rest of the World
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453